Is Comera Life Sciences Holdings, Inc. overvalued or undervalued?

As of 10 August 2023, the valuation grade for Comera Life Sciences Holdings, Inc. has moved from does not qualify to risky. The company appears to be overvalued based on its current financial metrics. The P/E ratio stands at -0.0007, while the EV to EBITDA and EV to EBIT ratios are both at 0.13, indicating significant financial distress compared to industry norms.
In comparison with peers, Tonix Pharmaceuticals Holding Corp. has a P/E ratio of -3.6690 and EV to EBITDA of -1.7982, while Cyclerion Therapeutics, Inc. shows a P/E of -3.0156 and EV to EBITDA of -1.8268, both of which reflect similar risk profiles. The company's return over the past year is notably poor at -99.2%, contrasting sharply with the S&P 500's return of 10.26% during the same period, reinforcing the notion that Comera Life Sciences is overvalued in its current state.